To report a rare case of locally advanced presumed G-CSF-producing hepatocellular carcinoma (HCC) and its successful management through conversion therapy, which refers to the treatment approach aimed at making an initially unresectable tumor resectable.
Key Findings:
The patient exhibited no specific clinical symptoms despite a massive tumor, highlighting the atypical presentation of G-CSF-producing HCC.
Combination therapy effectively downstaged the tumor to a resectable state, demonstrating the potential of this approach.
No recurrence was observed at 6-month follow-up, indicating successful management.
Interpretation:
Clinicians should consider G-CSF-producing HCC in patients with HCC and unexplained leukocytosis, as this may influence treatment decisions. A combined therapeutic approach may be viable for those not suitable for upfront resection, potentially improving outcomes.
Limitations:
Pre-treatment serum G-CSF levels were not measured.
Further studies are needed to validate the combined therapeutic approach.
Long-term follow-up data is necessary to assess the durability of treatment outcomes.
Conclusion:
This case highlights the potential for successful management of G-CSF-producing HCC through a combined therapeutic regimen.
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
